The UPCI Chemical Biology Facility (ChBF) has emerged from an innovative UPCI-supported pilot project to become a new Shared Facility. The overall goal ofthe ChBF is to ensure that UPCI members have access to the most modern chemical biology reagents, instrumentation, and personnel, which will enable them to identify unique chemical probes and potential anticancer leads for further optimization. The ChBF will provide high quality support services to UPCI researchers for: 1) high throughput screening (HTS) and high content screening (HCS) assay design, development, validation, and implementation, 2) small molecule and siRNA library distribution, 3) lead characterization and optimization, and 4) data analysis. A component ofthe ChBF's service will include supplying high quality, professional access to multiple automated liquid handlers for use in 96- and 384-well plate formats, detectors, large chemical libraries, siRNA libraries, chemical informatics, chemical analysis, analog acquisition, and sophisticated data analysis software. The ChBF will collaborate with UPCI faculty, staff, and trainees in developing and conducting cancer-relevant, cell-free and cell-based HTS and HCS assays. Training will be offered either on an individual or group basis depending on the perceived need or formal requests for training. Availability of ChBF resources will be disseminated through posts on the UPCI website, emails to UPCI members, and annual workshops, seminars, and poster presentations at the UPCI retreat. The ChBF is especially interested in promoting innovative assays at UPCI. Therefore, it will encourage the development and implementation of challenging cancer-related assays. In particular, the ChBF will promote novel HCS assays focused on targets that have traditionally been considered """"""""undruggable"""""""" as an innovative component of its activity within UPCI. The ChBF creates a starting point for the identification of unique chemical probes and lead structures for potential new therapies for all of UPCI's Programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705410
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$123,232
Indirect Cost
$41,711
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Low, Carissa A; Bovbjerg, Dana H; Ahrendt, Steven et al. (2018) Fitbit step counts during inpatient recovery from cancer surgery as a predictor of readmission. Ann Behav Med 52:88-92
Correa, Andres F; Toussi, Amir; Amin, Milon et al. (2018) Small Renal Masses in Close Proximity to the Collecting System and Renal Sinus Are Enriched for Malignancy and High Fuhrman Grade and Should Be Considered for Early Intervention. Clin Genitourin Cancer 16:e729-e733
Wang, Yi-Jun; Fletcher, Rochelle; Yu, Jian et al. (2018) Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis 5:194-203
Bakkenist, Christopher J; Lee, James J; Schmitz, John C (2018) ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer. Clin Colorectal Cancer 17:255-257
Beumer, Jan H; Chu, Edward; Allegra, Carmen et al. (2018) Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clin Pharmacol Ther :
Tasdemir, Nilgun; Bossart, Emily A; Li, Zheqi et al. (2018) Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. Cancer Res 78:6209-6222
Mazharuddin, Samir; Chattopadhyay, Anuja; Levy, Moshe Y et al. (2018) IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid. Leuk Lymphoma 59:2246-2249
Basudan, Ahmed; Priedigkeit, Nolan; Hartmaier, Ryan J et al. (2018) Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. Mol Cancer Res :
Pascal, Laura E; Wang, Yao; Zhong, Mingming et al. (2018) EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer. Neoplasia 20:351-363
Song, Xinxin; Zhu, Shan; Chen, Pan et al. (2018) AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc- Activity. Curr Biol 28:2388-2399.e5

Showing the most recent 10 out of 1187 publications